Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the completion of the transaction, the chief executive officer owned 1,647,546 shares in the company, valued at $48,750,886.14. The trade was a 10.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00.
• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.49, for a total transaction of $5,298,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded down $0.14 during midday trading on Wednesday, hitting $29.15. 8,451,804 shares of the company’s stock traded hands, compared to its average volume of 6,063,708. The firm’s fifty day moving average price is $28.14 and its two-hundred day moving average price is $23.42. Roivant Sciences Ltd. has a twelve month low of $10.57 and a twelve month high of $30.33. The company has a market cap of $20.86 billion, a PE ratio of -24.91 and a beta of 1.20.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ROIV shares. Piper Sandler upped their target price on Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Citigroup lifted their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.55.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG raised its position in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Morgan Stanley raised its holdings in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after acquiring an additional 6,877,348 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Roivant Sciences in the 4th quarter worth about $112,750,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.